Skip to main content

LINDIS Biotech Presented Encouraging Data from High Risk-Non-Muscle-Invasive Bladder Cancer Patients Treated with Trifunctional Antibody CATUMAXOMAB at EMUC22

Written by Kai Schmitz on . Posted in Client News.